by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia
Abstract INTRODUCTION Real-world modifiers of lecanemab benefit in Alzheimer’s disease (AD) remain elusive. We examined associations between caregiver positivity and longitudinal outcomes in AD. METHODS This seven-center longitudinal study followed 127...
by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia
Abstract INTRODUCTION Age-related cognitive decline and Alzheimer’s disease (AD) are strongly influenced by lipid metabolism, yet how central and peripheral lipid profiles relate to disease risk before symptom onset remains unclear. METHODS We performed...
by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia
Abstract INTRODUCTION Plasma β-synuclein is a promising blood-based synaptic biomarker, but relationships with synaptic density as indicated by [11C]UCB-J positron emission tomography (PET), and blood biomarkers of Alzheimer’s disease (AD) pathology,...
by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia
Abstract BACKGROUND Although lecanemab has demonstrated clinical efficacy in early Alzheimer’s disease (AD), its cost-effectiveness in China remains uncertain. This study evaluated the long-term cost-effectiveness of lecanemab in Chinese patients from a societal...
by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Neuropsychology (general)
Journal of Neuropsychology, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | October 27, 2026 Neuro-General Previous...
